Australia Lung Cancer Drugs Market Analysis Report [2022-30] I Insights10

Australia Lung Cancer Drugs Market Analysis

$ 3999

The Australia Lung Cancer Drug Market is projected to grow from $115 Mn in 2022 to $242 Mn by 2030, registering a CAGR of 9.80% during the forecast period of 2022 – 2030. The incidence of lung cancer in Australia has been increasing in recent years, due in part to the high rates of smoking in the country. Some of the key players in the lung cancer drug market in Australia include AstraZeneca, Roche, Merck, Pfizer, and Bristol-Myers Squibb.

ID: IN10AUPH015 CATEGORY: Pharmaceuticals GEOGRAPHY: Australia AUTHOR: Shivam Zalke

Buy Now

Australia Lung Cancer Drugs Market Executive Summary

The Australia Lung Cancer Drugs Market is projected to grow from $115 Mn in 2022 to $242 Mn by 2030, registering a CAGR of 9.80% during the forecast period of 2022 – 2030.

Australia is a wealthy and developed country with a strong and diversified economy. It is the world's 13th-largest economy and the sixth-largest in the Asia-Pacific region. The Australian economy is driven by a number of sectors, including mining, agriculture, manufacturing, and services. Australia is a wealthy and developed country with a strong and diversified economy. It is the world's 13th-largest economy and the sixth-largest in the Asia-Pacific region. The Australian economy is driven by several sectors, including mining, agriculture, manufacturing, and services. As of 2022, the gross domestic product (GDP) of Australia was approximately $1.725 Tn. Australia spent an anticipated $202.5 Bn on health-related products and services in 2019–2020 or $7,926 per person on average.

The lung cancer market in Australia is a significant part of the country's healthcare industry, with a high prevalence of lung cancer among the population. According to Cancer Australia, lung cancer is the most common cause of cancer-related deaths in the country, accounting for around 13% of all cancer deaths.

There are a number of treatments available for lung cancer in Australia, including surgery, chemotherapy, and radiation therapy. The type of treatment recommended will depend on the stage of cancer and the overall health of the patient.

According to the Australian Institute of Health and Welfare, the most common type of lung cancer in Australia is Non-small Cell Lung Cancer (NSCLC), which accounts for around 85% of all cases. The standard treatment for NSCLC is chemotherapy, and a number of chemotherapy drugs are available in the Australian market, including taxanes, platinum compounds, and alkylating agents.

There have also been a number of advances in the treatment of lung cancer in recent years, including the development of targeted therapies and immunotherapies. These drugs, which are designed to specifically target cancer cells and stimulate the immune system, have improved outcomes for many patients with lung cancer.

Some of the key players in the lung cancer drugs market in Australia include pharmaceutical companies such as AstraZeneca, Roche, and Merck, which produce a range of chemotherapy drugs and targeted therapies for the treatment of lung cancer.

Overall, the lung cancer drugs market in Australia is expected to continue to grow in the coming years, as the population ages and the incidence of lung cancer increases.

australia lung cancer drugs market

Market Dynamics

Market Growth Drivers and Restraints

The lung cancer market in Australia is characterized by a number of key trends, including:

Increasing incidence of lung cancer: The incidence of lung cancer in Australia has been increasing in recent years, due in part to the high rates of smoking in the country.
Advances in treatment: There have been a number of advances in the treatment of lung cancer in recent years, including the development of targeted therapies and immunotherapies, which have improved outcomes for many patients.
Growing demand for minimally-invasive procedures: There is a growing demand for minimally-invasive procedures for the treatment of lung cancer in Australia, such as video-assisted thoracoscopic surgery (VATS), which can reduce the need for open surgery and result in faster recovery times for patients.
Increasing use of telehealth: The COVID-19 pandemic has led to an increase in the use of telehealth in the treatment of lung cancer in Australia, with many patients opting to receive treatment remotely in order to reduce the risk of infection.

Competitive Landscape

Key Players

Some of the key players in the lung cancer drugs market in Australia include:

AstraZeneca: AstraZeneca is a global pharmaceutical company that produces a range of chemotherapy drugs and targeted therapies for the treatment of lung cancer, including Iressa and Tagrisso.
Roche: Roche is a global healthcare company that produces a range of chemotherapy drugs and targeted therapies for the treatment of lung cancer, including Tarceva and Avastin.
Merck: Merck is a global pharmaceutical company that produces a range of chemotherapy drugs and targeted therapies for the treatment of lung cancer, including Keytruda and Lynparza.
Pfizer: Pfizer is a global pharmaceutical company that produces a range of chemotherapy drugs and targeted therapies for the treatment of lung cancer, including Xalkori and Sutent.
Bristol-Myers Squibb: Bristol-Myers Squibb is a global pharmaceutical company that produces a range of chemotherapy drugs and targeted therapies for the treatment of lung cancer, including Opdivo and Yervoy.

Healthcare Policies and Regulatory Landscape

According to the Therapeutic Goods Act 1989 (Cth) and its delegated legislation, the Therapeutic Goods Administration (TGA), the Commonwealth regulator, is responsible for overseeing the regulation of therapeutic goods in Australia, including prescription drugs, over-the-counter drugs, complementary medicines, medical devices, and certain blood and blood products. The TGA is in charge of examining, judging, and keeping track of products that are produced or supplied in, exported from, or imported into Australia.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Drugs Market Segmentation

By Disease type

Small Cell Lung Cancer (SCLC)
Non-Small Cell Lung Cancer (NSCLC)

By Drug

Gemzar
Paraplatin
Texotere
Others

By End-user

Hospitals
Clinics
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.